Purine and pyrimidine nucleotides play a crucial role in virtually all biological processes. As described in the following presentations, these nucleotides are derived exclusively from endogenous sources in humans: a combination of de nouo synthesis, i.e. multistep synthetic pathways utilizing simple precursors (ammonia, bicarbonate, amino acids, etc.), and 'salvage', i.e. the recycling of preformed purine bases or pyrimidine nucleosides, with salvaged nucleotides normally exerting feedback control on de nooo synthesis [ 11. This colloquium focuses on structural and functional studies of enzymes controlling individual steps in the pathways of nucleotide biosynthesis, and the application of this information to the development of more effective anti-proliferative, immunosuppressive and anti-parasitic drugs. This is a worthy goal, for to understand the abnormal requires a clear picture of the normal. What is not always appreciated is that there are considerable differences between prokaryotes and eukaryotes, as well as between different mammalian species, and in particular tissue-specific differences in enzyme expression within a given species [2] . For instance, microorganisms salvage pyrimidines at the base level and purines at the nucleoside level, the converse of the situation in humans, representing an important focus for devising therapy that is selectively lethal to the invader but not to the host.
Another problem is that information gleaned from disrupted cells, or from studies in uitro, is not necessarily applicable to the in oivo situation [ 13. Much of our knowledge relating to the interaction between the synthetic and salvage pathways in normal humans comes from studies in patients with genetic defects of enzymes catalysing individual steps in these pathways. From these patients we have learnt that salvage of purines is essential for the control of de novo synthesis and for as yet unexplained reasons for the brain, but not for the immune system (reviewed in [2] ). However, removal of the toxic purine waste from DNA turnover is vital to the immune system, and indeed to all rapidly dividing cells, to ensure a balanced supply of precursors for the cell-cycle-specific enzyme ribonucleotide reductase. The pyrimidine disorders confirm the importance of de nouo synthesis and salvage to the immune and haematopoietic systems, as well as to the central nervous system. The fact that hereditary oroticaciduria does respond to life-long uridine indicates that pyrimidine salvage can compensate for the genetic lack of de novo synthesis, due to blockage at the level of UMP synthase, even in rapidly dividing cells such as lymphocytes.
The anucleate erythrocyte is an interesting example of cell co-operativity [1,2]. It does not salvage uridine, but readily picks up orotic acid, which it recycles to deliver as uridine to other tissues. The reverse is true of nucleated cells, which salvage uridine but not orotic acid. The erythrocyte also picks up adenosine, which, in the absence of de novo synthesis, it uses to sustain its ATP [2] . The malarial parasite, as described in the paper by Christopherson and co-workers, can only synthesize pyrimidines de novo, and not purines; it is dependent on salvage for purines, but not pyrimidines. Again these are 877 -I995 Biochemical Society Transactions important differences which are being exploited therapeutically [3] .
It is a commonly held belief that nucleated cells have a requirement for a balanced supply of purine and pyrimidine nucleotides, but is this true for all cells? Our own recent studies [4] accord with those of others [5] and indicate that this does not apply to phytohaemagglutininstimulated T-lymphocytes, where expansion of the cytosolic pyrimidine nucleotide pool is up to 4-fold greater than for purines. The importance of de novo synthesis for this is highlighted by (a) the arrest in the expansion of all pools from 24 h by the glutamine antagonist azaserine, indicating complete blockage of pyrimidine, NAD', and purine synthesis; and (b) the G T P depletion and cell cycle arrest at 48 h induced by ribavirin, with pyrimidine nucleotide depletion evident at 72 h. This confirms that T-lymphocytes need to activate their synthetic pathways to provide the additional ribonucleotide precursors necessary not only for RNA and DNA synthesis, but also for the other processes associated with cell division, e.g. the purine and pyrimidine sugars essential for membrane lipid synthesis and protein glycosylation, and the pyrimidine nucleotides required for strand-break repair.
The human lymphocyte has been of particular interest because of its role in the immune response, and it may be an example of a situation where the allosteric controls on de novo synthesis are quite different from those in other cells. In contrast to most cells where phosphoribosylpyrophosphate synthase (EC 2.7.6.1) is normally subject to feedback inhibition by both adenosine and guanosine nucleotides, this enzyme in human lymphocytes is seemingly inhibited by adenosine nucleotides, but stimulated by guanosine nucleotides [6] . Consequently, inhibitors of G T P synthesis have been the focus of strategies to induce immunosuppression in organ transplantation, and several novel drugs are now in mentary stimulation of de novo pyrimidine biosynthesis [9, 10] . This contrasts with the inhibition of both pyrimidine and purine synthesis found by us in blasting T-lymphocytes [4] and suggests that allosteric regulation of pyrimidine metabolism may also differ in normal lymphocytes [6] .
Another interesting question is: do viruses, as well as bacterial and parasitic infections, alter the purine and pyrimidine metabolism of the host cell in a manner that is detrimental to normal function? Our recent studies in HIV-1' lymphocytes suggests that they do. A striking abnormality already detectable in cells from asymptomatic patients was the impaired ability of pyrimidine pools to expand in response to mitogen stimulation, although purine responses were normal, while in cells from symptomatic patients de novo synthesis of both purines and pyrimidines was seriously impaired [ l l ] . These findings underline the particular importance of pyrimidine ribonucleotide availability to proliferating T-lymphocytes.
In summary, when studying the enzymes of nucleotide biosynthesis it is important to remember that: (a) activity in disrupted cells may not reflect the in vivo situation; (b) differences between humans, micro-organisms and other mammalian species can be considerable; (c) there are remarkable tissue-specific variations in enzyme expression within a given species; (d) the requirements of cells undergoing rapid division may vary from those of normal cells, and hence the regulatory controls might be quite different; and (e) as we shall see in the different presentations in this colloquium, important differences may exist between normal, parasiteinfected and malignant cells which can be exploited to the benefit of the healthy cell, while avoiding toxic side-effects.
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clinical trial [6, 7] . Numerous studies also point to important differences in controls between malignant and normal lymphocytes, such as the rapid incorporation of salvaged uridine into cytidine nucleotides by malignant but not blasting lymphocytes L8]* It is generally assumed from studies in cultured cells that a decrease in purine synthesis de novo results in a corresponding stimulation of pyrimidine synthesis [ 11. T h e antagonists azaserine and ribavirin, which inhibit de novo purine synthesis in malignant lymphocytes, have been reported to induce a comple-
